文献速递糖尿病

接受胰岛素治疗的老年2型糖尿病患者中持续葡萄糖监测设备的总体使用情况及种族、民族和社会经济差异

Overall Uptake and Racial, Ethnic, and Socioeconomic Disparities in the Use of Continuous Glucose Monitoring Devices Among Insulin-Treated Older Adults With Type 2 Diabetes.
PubMed 文献 · Diabetes Care · 2025-01-01

该研究利用美国Medicare按服务收费(2013—2020)与Optum去标识化Clinformatics数据库(2013—2022)数据,评估接受胰岛素治疗的老年2型糖尿病患者持续葡萄糖监测(CGM)启动率的时间趋势及相关因素。CGM年启动率从Medicare的107/10万升至5,249/10万、Clinformatics的796/10万升至9,195/10万,但总体仍<10%;西班牙裔和黑人患者较白人更少启动CGM,年龄较大和低社会经济地位地区也与较低CGM使用相关。

要点

  • 接受胰岛素治疗的老年2型糖尿病患者中CGM启动率随时间上升,但总体仍<10%。
  • 西班牙裔和黑人患者较白人患者启动CGM的可能性更低。
  • 年龄较大和居住于低社会经济地位地区与较低CGM使用相关。

核心结论

  • CGM启动率随时间增加,但在接受胰岛素治疗的老年2型糖尿病患者中仍<10%,并观察到显著的种族、民族和社会经济差异。

研究设计与样本

  • 利用Medicare按服务收费(2013—2020)和Optum去标识化Clinformatics数据市场数据库(2013—2022)数据,识别每年启动CGM的≥65岁接受胰岛素治疗的2型糖尿病患者。
  • CGM启动依据当前程序术语编码和国家药品代码定义。
  • 采用风险集抽样将CGM新使用者按1:4匹配至未暴露于CGM的患者,索引日期为CGM启动日期或对照者±7天内最近的医生就诊日期。
  • 使用逻辑回归评估与CGM启动相关的人口学和临床特征。

主要发现

  • Medicare中CGM年启动率从107/10万升至5,249/10万(2013—2020),Clinformatics中从796/10万升至9,195/10万(2013—2022)。
  • 与白人患者相比,西班牙裔患者启动CGM的比值比在Medicare为0.44(95%CI 0.42-0.48)、在Clinformatics为0.81(95%CI 0.78-0.85)。
  • 与白人患者相比,黑人患者启动CGM的比值比在Medicare为0.71(95%CI 0.69-0.73)、在Clinformatics为0.89(95%CI 0.85-0.92)。
  • 年龄较大和居住于低社会经济地位地区与较低的CGM使用相关。
  • 有低血糖史和较低衰弱评分增加CGM启动的可能性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess time trends of and examine which sociodemographic and clinical characteristics are associated with continuous glucose monitoring (CGM) initiation in insulin-treated older adults with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Using data from Medicare Fee-for-Service (2013-2020) and Optum's deidentified Clinformatics Data Mart Database (Clinformatics) (2013-2022), we identified patients aged ≥65 years with T2D receiving insulin therapy who initiated CGM annually. Initiation of a CGM device was defined based on Current Procedural Terminology codes and National Drug Codes. Then, we 1:4 matched new users of CGM to patients unexposed to CGM, using risk set sampling. Index date was the date of CGM initiation or, for control participants, the closest physician visit within ±7 days. We used logistic regression to assess demographic and clinical characteristics associated with CGM initiation. RESULTS: The annual CGM initiation rate rose from 107 to 5,249/100,000 in Medicare (2013-2020) and from 796 to 9,195/100,000 in Clinformatics (2013-2022). Compared with White patients, Hispanic (odds ratio, 96% CI: 0.44, 0.42-0.48 in Medicare and 0.81, 0.78-0.85 in Clinformatics) and Black (0.71, 0.69-0.73 in Medicare and 0.89, 0.85-0.92 in Clinformatics) individuals were less likely to receive CGM. Older age and residing in low socioeconomic status areas were associated with lower CGM uptake, while history of hypoglycemia and lower frailty scores increased CGM initiation likelihood. CONCLUSIONS: CGM initiation has increased over time but remains <10% among insulin-treated older adults with T2D. Substantial racial, ethnic, and socioeconomic disparities were observed.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Alkabbani W, Cromer SJ, Kim DH, et al. Overall Uptake and Racial, Ethnic, and Socioeconomic Disparities in the Use of Continuous Glucose Monitoring Devices Among Insulin-Treated Older Adults With Type 2 Diabetes. Diabetes Care. 2025. PMID: 40445849. doi:10.2337/dca25-0006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。